Daria Artamonova

Daria Artamonova

Auto-generated profile, based on publicly available information

Daria Artamonova

Center for Molecular and Cellular Biology, Skolkovo Institute of Science and Technology, Moscow 121205, Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Cell
Verified
Journal Article
Closed access
LYLilan You
Lilan You
JMJun Ma
Jun Ma
JWJiuyu Wang
Jiuyu Wang
DADaria Artamonova
Daria Artamonova
MWMin Wang
Min Wang
YWYanli Wang
Yanli Wang

20 October 2021 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
MKMatvey Kolesnik
Matvey Kolesnik
IFIana Fedorova
Iana Fedorova
KKKaryna A. Karneyeva
Karyna A. Karneyeva
DADaria N. Artamonova
Daria N. Artamonova
KSKonstantin Severinov
Konstantin Severinov
The emergence and persistence of selfish genetic elements is an intrinsic feature of all living systems. Cellular organisms have evolved a plethora of elaborate defense systems that limit the spread of such genetic parasites. CRISPR-Cas are RNA-guided defense systems used by prokaryotes to recognize and destroy foreign nucleic acids. These systems acquire and store fragments of foreign nucleic acids and utilize the stored sequences as guides to recognize and destroy genetic invaders. CRISPR-Cas systems have been extensively studied, as some of them are used in various genome editing technologies. Although Type III CRISPR-Cas systems are among the most common CRISPR-Cas systems, they are also some of the least investigated ones, mostly due to the complexity of their action compared to other CRISPR-Cas system types. Type III effector complexes specifically recognize and cleave RNA molecules. The recognition of the target RNA activates the effector large subunit – the so-called CRISPR polymerase – which cleaves DNA and produces small cyclic oligonucleotides that act as signaling molecules to activate auxiliary effectors, notably non-specific RNases. In this review, we provide a historical overview of the sometimes meandering pathway of the Type III CRISPR research. We also review the current data on the structures and activities of Type III CRISPR-Cas systems components, their biological roles, and evolutionary history. Finally, using structural modeling with AlphaFold2, we show that the archaeal HRAMP signature protein, which heretofore has had no assigned function, is a degenerate relative of Type III CRISPR-Cas signature protein Cas10, suggesting that HRAMP systems have descended from Type III CRISPR-Cas systems or their ancestors.

25 March 2019 in Philosophical Transactions of the Royal Society B: Biological Sciences
Verified
Journal Article
Open access
ALAnna Lopatina
Anna Lopatina
SMSofia Medvedeva
Sofia Medvedeva
DADaria Artamonova
Daria Artamonova
MKMatvey Kolesnik
Matvey Kolesnik
VSVasily Sitnik
Vasily Sitnik
KSKonstantin Severinov
Konstantin Severinov
We investigated the diversity of CRISPR spacers of Thermus communities from two locations in Italy, two in Chile and one location in Russia. Among the five sampling sites, a total of more than 7200 unique spacers belonging to different CRISPR-Cas systems types and subtypes were identified. Most of these spacers are not found in CRISPR arrays of sequenced Thermus strains. Comparison of spacer sets revealed that samples within the same area (separated by few to hundreds of metres) have similar spacer sets, which appear to be largely stable at least over the course of several years. While at further distances (hundreds of kilometres and more) the similarity of spacer sets is decreased, there are still multiple common spacers in Thermus communities from different continents. The common spacers can be reconstructed in identical or similar CRISPR arrays, excluding their independent appearance and suggesting an extensive migration of thermophilic bacteria over long distances. Several new Thermus phages were isolated in the sampling sites. Mapping of spacers to bacteriophage sequences revealed examples of local acquisition of spacers from some phages and distinct patterns of targeting of phage genomes by different CRISPR-Cas systems. This article is part of a discussion meeting issue ‘The ecology and evolution of prokaryotic CRISPR-Cas adaptive immune systems’.

21 August 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
DADaria Artamonova
Daria Artamonova
KKKaryna Karneyeva
Karyna Karneyeva
SMSofia Medvedeva
Sofia Medvedeva
EKEvgeny Klimuk
Evgeny Klimuk
MKMatvey Kolesnik
Matvey Kolesnik
KSKonstantin Severinov
Konstantin Severinov
Type III CRISPR–Cas systems provide immunity to foreign DNA by targeting its transcripts. Target recognition activates RNases and DNases that may either destroy foreign DNA directly or elicit collateral damage inducing death of infected cells. While some Type III systems encode a reverse transcriptase to acquire spacers from foreign transcripts, most contain conventional spacer acquisition machinery found in DNA-targeting systems. We studied Type III spacer acquisition in phage-infected Thermus thermophilus, a bacterium that lacks either a standalone reverse transcriptase or its fusion to spacer integrase Cas1. Cells with spacers targeting a subset of phage transcripts survived the infection, indicating that Type III immunity does not operate through altruistic suicide. In the absence of selection spacers were acquired from both strands of phage DNA, indicating that no mechanism ensuring acquisition of RNA-targeting spacers exists. Spacers that protect the host from the phage demonstrate a very strong strand bias due to positive selection during infection. Phages that escaped Type III interference accumulated deletions of integral number of codons in an essential gene and much longer deletions in a non-essential gene. This and the fact that Type III immunity can be provided by plasmid-borne mini-arrays open ways for genomic manipulation of Thermus phages.

5 November 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
IFIana Fedorova
Iana Fedorova
AVAleksandra Vasileva
Aleksandra Vasileva
PSPolina Selkova
Polina Selkova
MAMarina Abramova
Marina Abramova
AAAnatolii Arseniev
Anatolii Arseniev
KSKonstantin Severinov
Konstantin Severinov
CRISPR-Cas defense systems opened up the field of genome editing due to the ease with which effector Cas nucleases can be programmed with guide RNAs to access desirable genomic sites. Type II-A SpCas9 from Streptococcus pyogenes was the first Cas9 nuclease used for genome editing and it remains the most popular enzyme of its class. Nevertheless, SpCas9 has some drawbacks including a relatively large size and restriction to targets flanked by an ‘NGG’ PAM sequence. The more compact Type II-C Cas9 orthologs can help to overcome the size limitation of SpCas9. Yet, only a few Type II-C nucleases were fully characterized to date. Here, we characterized two Cas9 II-C orthologs, DfCas9 from Defluviimonas sp.20V17 and PpCas9 from Pasteurella pneumotropica. Both DfCas9 and PpCas9 cleave DNA in vitro and have novel PAM requirements. Unlike DfCas9, the PpCas9 nuclease is active in human cells. This small nuclease requires an ‘NNNNRTT’ PAM orthogonal to that of SpCas9 and thus potentially can broaden the range of Cas9 applications in biomedicine and biotechnology.

16 January 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
IFIana Fedorova
Iana Fedorova
AAAnatolii Arseniev
Anatolii Arseniev
PSPolina Selkova
Polina Selkova
GPGeorgii Pobegalov
Georgii Pobegalov
IGIgnatiy Goryanin
Ignatiy Goryanin
KSKonstantin Severinov
Konstantin Severinov
Type II CRISPR–Cas9 RNA-guided nucleases are widely used for genome engineering. Type II-A SpCas9 protein from Streptococcus pyogenes is the most investigated and highly used enzyme of its class. Nevertheless, it has some drawbacks, including a relatively big size, imperfect specificity and restriction to DNA targets flanked by an NGG PAM sequence. Cas9 orthologs from other bacterial species may provide a rich and largely untapped source of biochemical diversity, which can help to overcome the limitations of SpCas9. Here, we characterize CcCas9, a Type II-C CRISPR nuclease from Clostridium cellulolyticum H10. We show that CcCas9 is an active endonuclease of comparatively small size that recognizes a novel two-nucleotide PAM sequence. The CcCas9 can potentially broaden the existing scope of biotechnological applications of Cas9 nucleases and may be particularly advantageous for genome editing of C. cellulolyticum H10, a bacterium considered to be a promising biofuel producer.